Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard-Karls-University Hospitals and Clinics, Wilhelmstr. 56, 72074, Tübingen, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):299-311. doi: 10.1007/s00210-011-0709-8. Epub 2011 Nov 15.
The pancreatic K(ATP) channel, SUR1/Kir6.2, couples insulin secretion to the plasma glucose level. The channel is an octamer with four Kir6.2 subunits forming the pore and four sulphonylurea receptors (SUR1) regulating channel activity. SUR1 is an ABC protein with adenosine triphosphate (ATP)ase activity which activates the channel. It also contains the binding site for antidiabetic drugs like glibenclamide and repaglinide which close the channel by disrupting the stimulatory effect SUR-ATPase (MgATP-dependent) and by stabilising a long-lived closed channel state (MgATP-independent). In this study, we examined the effects of progressive truncation of the Kir6.2 N-terminus up to 20 amino acids on equilibrium binding and channel closure by glibenclamide and repaglinide, on the channel activating effect of the opener, 6-chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4thiadiazine 1,1-dioxide (NNC 55-0462), and on the binding kinetics of [(3)H]glibenclamide. Kir and SUR were transiently coexpressed in HEK cells and [(3)H]glibenclamide binding and patch-clamp experiments were performed in whole cells at 37°C and in isolated inside/out patches at 22°C. Truncation of the first 5 N-terminal amino acids abolished most of the affinity increase for glibenclamide and repaglinide that is produced by the association of Kir6.2 with SUR1. Progressive truncation continuously reduced the potency and efficacy of these drugs in closing the channel and impaired the ability to stabilise the closed state more than the ability to disrupt channel stimulation by SUR-ATPase. The effects of NNC 55-0462 were unchanged. Progressive truncation also speeded up dissociation of [(3)H]glibenclamide from the channel when dissociation was induced by an excess of (unlabelled) glibenclamide. This suggests the existence of a putative low affinity glibenclamide site on the channel whose affinity increases upon truncation. The data show that progressive truncation of the Kir6.2 N-terminus impairs the transduction of drug binding into channel closure more strongly than drug binding but leaves the effect of the opener NNC 55-0462 unchanged.
胰腺 K(ATP) 通道,由 SUR1/Kir6.2 组成,将胰岛素分泌与血糖水平联系起来。该通道是一个由四个 Kir6.2 亚基组成的八聚体,形成通道,四个磺酰脲受体 (SUR1) 调节通道活性。SUR1 是一种具有三磷酸腺苷 (ATP) 酶活性的 ABC 蛋白,可激活通道。它还包含与抗糖尿病药物如格列本脲和瑞格列奈结合的位点,通过破坏 SUR-ATP 酶的刺激作用(MgATP 依赖性)和稳定长寿命的关闭通道状态(MgATP 独立性)来关闭通道。在这项研究中,我们检查了 Kir6.2 N 末端截短至 20 个氨基酸对格列本脲和瑞格列奈平衡结合和通道关闭、 opener 6-氯-3-(1-甲基环丁基)氨基-4H-噻吩[3,2-e]-1,2,4 噻二嗪 1,1-二氧化物 (NNC 55-0462) 的通道激活作用以及 [(3)H]格列本脲结合动力学的影响。Kir 和 SUR 瞬时共表达在 HEK 细胞中,在 37°C 下的整个细胞中和在 22°C 下的分离内外斑块中进行 [(3)H]格列本脲结合和膜片钳实验。截短第一个 5 个 N 端氨基酸消除了 Kir6.2 与 SUR1 结合后格列本脲和瑞格列奈亲和力增加的大部分。随着截短的进行,这些药物关闭通道的效力和效力逐渐降低,并损害稳定关闭状态的能力超过破坏 SUR-ATP 酶对通道刺激的能力。NNC 55-0462 的作用保持不变。截短还加速了 [(3)H]格列本脲从通道上的解离,当用过量(未标记)格列本脲诱导解离时。这表明通道上存在一个假定的低亲和力格列本脲结合位点,其亲和力在截短后增加。数据表明,Kir6.2 N 末端的逐渐截短对药物结合转化为通道关闭的影响比药物结合更强,但对 opener NNC 55-0462 的作用没有影响。